Status:
TERMINATED
Benazepril Hydrochloride, Lisinopril, Ramipril, or Losartan Potassium in Treating Hypertension in Patients With Solid Tumors
Lead Sponsor:
Wake Forest University Health Sciences
Conditions:
Hypertension
Unspecified Adult Solid Tumor, Protocol Specific
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Benazepril hydrochloride, lisinopril, ramipril, and losartan potassium may help lower blood pressure. PURPOSE: This phase II trial is studying how well benazepril hydrochloride, lisinopril...
Detailed Description
PRIMARY OBJECTIVES: I. To determine which drug has the greatest effect on Ang-(1-7) levels in cancer patients with hypertension. SECONDARY OBJECTIVES: I. To determine the effect of these drugs on l...
Eligibility Criteria
Inclusion
- Patients must have histologically or cytologically confirmed solid tumor malignancy AND hypertension, defined as a systolic pressure \> 130 OR a diastolic pressure \> 80
- Patients cannot be on active chemotherapy or radiation therapy; start of treatment with ACE-I or ARB must occur at least four weeks after the last dose of chemotherapy or radiation therapy
- Creatinine \< 2.5
- Potassium \< ULN
- Ability to understand and the willingness to sign a written informed consent document
- HIV positive patients are eligible to participate in this study
Exclusion
- Patients who are pregnant or nursing due to significant risk to the fetus/infant
- Patients who are unable to take oral medications
- Patients who are currently taking an ACE-Inhibitor or ARB
Key Trial Info
Start Date :
February 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2014
Estimated Enrollment :
6 Patients enrolled
Trial Details
Trial ID
NCT01234922
Start Date
February 1 2011
End Date
April 1 2014
Last Update
August 28 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157